This invention is a family of fluorinated small-molecule carbamates that activate the KCNQ2/3 (Kv7.2/Kv7.3) potassium channel, a key brake on neuronal hyperexcitability. Select compounds in the series show markedly improved selectivity for KCNQ2/3 over related peripheral Kv7 channels, which could support safer treatment of tinnitus and epilepsy.
Description
The compounds are built on a substituted triaminobenzene core carrying a carbamate group. The core is linked through an amine to a trifluoromethyl-substituted benzyl or pyridinyl ring. The compounds bind and open KCNQ2/3 channels, which increases ion flow and lowers neuronal excitability. Over-excitable neurons underlie conditions such as epilepsy and tinnitus.
The design rests on systematic placement of fluorine, trifluoromethyl and pentafluorosulfanyl groups, together with the choice of carbamate (ethyl, isopropyl or cyclopropyl). Small changes in these groups shift both potency and channel selectivity. Selected analogs retain sub-micromolar to low-micromolar potency at KCNQ2/3 while showing little or no activity at KCNQ3/5, KCNQ4 and KCNQ4/5. One substitution is also positioned to block the oxidative dimerization reported for retigabine. The compounds can be formulated as pharmaceutical compositions for oral, parenteral and other routes.
Applications
- Treatment or prevention of tinnitus
- Treatment of epilepsy, including as an add-on to existing anti-epileptic drugs
- Potential treatment of neuropathic pain
- Potential treatment of anxiety, depression, mania, ADHD and migraine
- Lead scaffolds for developing more subtype-selective Kv7 modulators, including Kv7.4/Kv7.5-selective agents for overactive bladder and irritable bowel syndrome
Advantages
- Selectivity for KCNQ2/3 over KCNQ4/5 up to a selectivity index above 10 for select analogs, versus about 0.3 for the earlier lead
- Sub-micromolar potency at KCNQ2/3 for several analogs (EC2x about 0.1 µM for the most potent)
- Tunable potency and selectivity through fluorine-based substitution
- Structural design aimed at avoiding the oxidative dimerization seen with retigabine
- Adaptable to multiple dosage forms and routes of administration
Invention Readiness
Around 20 analogs have been synthesized and fully characterized. Their potency and selectivity were profiled in a high-throughput automated electrophysiology assay in HEK293 cells expressing KCNQ2/3, KCNQ3/5, KCNQ4 and KCNQ4/5 channels. The data show several leads with strong potency and a selectivity index above 10. Electrostatic modeling supports a structure–activity rationale. Next steps include in vivo efficacy testing in tinnitus and epilepsy models, pharmacokinetic and safety evaluation, and formulation work toward preclinical development.
IP Status
https://patents.google.com/patent/US11358930B2/en?oq=11358930Related Publication(s)
Hernandez, Ciria C., et al. "Development of an automated screen for Kv7. 2 potassium channels and discovery of a new agonist chemotype." Bioorganic & medicinal chemistry letters 71 (2022): 128841. https://doi.org/10.1016/j.bmcl.2022.128841
Marinos, Laura, et al. "Transient delivery of a KCNQ2/3-specific channel activator 1 week after noise trauma mitigates noise-induced tinnitus." Journal of the Association for Research in Otolaryngology 22.2 (2021): 127-139. https://doi.org/10.1007/s10162-021-00786-3